Long-term experience using high-dose stereotactic body radiotherapy (SBRT) confirms that this highly focused, rigidly delivered, and tightly controlled radiation approach results in excellent local ...

Stereotactic body radiotherapy (SBRT) showed good local control and survival for limited metastatic/progressive cancers. Two-thirds of patients were alive at 2 years with minimal serious toxicity ...

Researchers from The University of Texas MD Anderson Cancer Center will present new data at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting demonstrating that stereotactic body ...

Study is the first to compare 10-year outcomes from surgery and a specific kind of radiation therapy known as SBRT (also called SABR) in non-small cell lung cancer Survival outcomes were similar, but ...

SAN FRANCISCO ― There was no significant increase in late toxicity when stereotactic body radiation therapy (SBRT) was used in the treatment of early-stage ― but inoperable ― non–small-cell lung ...

Patients in their 80s and 90s who have early stage lung cancer but cannot undergo an operation can be treated safely and effectively with stereotactic body radiation therapy (SBRT), according to ...

Osimertinib Versus First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Metastatic EGFR-Mutant Non–Small Cell Lung Cancer: A Target Trial Emulation Study of Real-World ...

A recent study published in the Journal of the American Medical Association revealed that among patients with early-stage non ...

The theme for the 2025 American Society for Radiation Oncology (ASTRO) annual meeting was "Rediscovering Radiation Medicine and Exploring New Indications." In both small-cell lung cancer (SCLC) and ...